A trial of clarithromycin for the treatment of suboptimally controlled asthma

E. Rand Sutherland, MD, MPH, Tonya S. King, PhD, Nikolina Icitovic, MAS, Bill T. Ameredes, PhD, Eugene Bleecker, MD, Homer A. Boushey, MD, William J. Calhoun, MD, Mario Castro, MD, MPH, Reuben M. Cherniack, MD, Vernon M. Chinchilli, PhD, Timothy J. Craig, DO, Loren Denlinger, MD, PhD, Emily A. DiMango, MD, John V. Fahy, MD, Elliot Israel, MD, Nizar Jarjour, MD, Monica Kraft, MD, Stephen C. Lazarus, MD, Robert F. Lemanske, Jr, MD, Stephen P. Peters, MD, Joe Ramsdell, MD, Christine A. Sorkness, PharmD, Stanley J. Szefler, MD, Michael J. Walter, MD, Stephen I. Wasserman, MD, Michael E. Wechsler, MD, Messr, Hong Wei Chu, MD, and Richard J. Martin, MD, for the National Heart, Lung and Blood Institute’s Asthma Clinical Research Network

Background: PCR studies have demonstrated evidence of Mycoplasma pneumoniae and Chlamydia pneumoniae in the lower airways of patients with asthma.

Objective: To test the hypothesis that clarithromycin would improve asthma control in individuals with mild-to-moderate persistent asthma that was not well controlled despite treatment with low-dose inhaled corticosteroids.

Methods: Adults with an Asthma Control Questionnaire score ≥1.5 after a 4-week period of treatment with fluticasone propionate were entered into a PCR-stratified randomized, controlled trial to evaluate the effect of 16 weeks of either clarithromycin or placebo, added to fluticasone, on asthma control in individuals with or without lower airway PCR evidence of M pneumoniae or C pneumoniae.

Results: A total of 92 participants were randomized. Twelve (13%) subjects demonstrated PCR evidence of M pneumoniae or C pneumoniae in endobronchial biopsies; 80 were PCR-negative for both organisms. In PCR-positive participants, clarithromycin yielded a 0.4 ± 0.4 unit improvement in the Asthma Control Questionnaire score, with a 0.1 ± 0.3 unit improvement in those allocated to placebo. This between-group difference of 0.3 ± 0.5 (P = .6) was neither clinically nor statistically significant. In PCR-negative participants, a nonsignificant between-group difference of 0.2 ± 0.2 units (P = .3) was observed. Clarithromycin did not improve lung function or airway inflammation but did improve airway hyperresponsiveness, increasing the methacholine PC20 by 1.2 ± 0.5 doubling doses (P = .02) in the study population.

Conclusion: Adding clarithromycin to fluticasone in adults with mild-to-moderate persistent asthma that was suboptimally controlled by low-dose inhaled corticosteroids alone did not further improve asthma control. Although there was an improvement in airway hyperresponsiveness with clarithromycin, this benefit was not accompanied by improvements in other secondary outcomes. (J Allergy Clin Immunol 2010;126:747-53.)

Key words: Asthma, infection, antibiotic

From the National Jewish Health, Denver, CO, Pennsylvania State University, College of Medicine, Hershey; University of Texas, Medical Branch, Galveston; Wake Forest University, School of Medicine, Winston-Salem; University of California, San Francisco; Washington University, School of Medicine, St. Louis; University of Wisconsin, Madison; Columbia University Medical Center, New York; Brigham and Women’s Hospital, Boston; Duke University, School of Medicine, Durham; University of California, San Diego Medical Center, San Diego; University of Wisconsin, School of Pharmacy, Madison.

Supported by NIH/NHLBI U10 HL074227, 074231, 074204, 074212, 074073, 074206, 074208, 074225, 074218, NIH/NHLBI K23 HL04385, and NIH UL1 RR025011.

Disclosure of potential conflict of interest: E. R. Sutherland is an advisor and data and safety monitoring board member for GlaxoSmithKline, an advisor for Dey, LP, and a data and safety monitoring board member for Merck and has received research support from the National Institutes of Health, Novartis, and Boehringer-Ingelheim. E. Bleecker is an advisor/consultant for Aerovance, AstraZeneca, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Merck, Novartis, Pfizer, and Wyeth and has received research support from Aerovance, Amgen, AstraZeneca, Boehringer-Ingelheim, Centocor, Cepion, Genentech, GlaxoSmithKline, Novartis, Pfizer, Wyeth, and the National Institutes of Health. A. A. Boushey has consulted for KaleoBios, has served on advisory committees for Pharmacix and GlaxoSmithKline, and has received research support from the National Institutes of Health. H. T. Crag has given talks for Novartis, and has received research support from GlaxoSmithKline, M. Castro, V. M. Chinchilli, and W. J. F. Walter has received research support from the National Institutes of Health. J. T. Crag has given talks for Teva, Merck, AstraZeneca, and Novartis and has received research support from GlaxoSmithKline, Boehringer-Ingelheim, Genentech, and Forest. J. F. Vahy has consulted for Amira, Cytokinetix, Abbott, GlaxoSmithKline, and Amgen and has received research support from GlaxoSmithKline, Boehringer-Ingelheim, Genentech, and the National Institutes of Health. E. Israel has received research support from the National Institutes of Health and provided legal consultation or expert witness testimony on the subject of asthma. N. Jarjour has consulted for Asthma and Genentech and has received research support from GlaxoSmithKline, Merck, and MedImmune. M. Kraft, through Duke University, has received research support from Merck, GlaxoSmithKline, GE Healthcare, Biomark, and the National Institutes of Health. S. C. Lazarus and R. J. Martin have received research support from the National Heart, Lung, and Blood Institute. R. F. Lemanske, Jr, has given talks for Merck, Medicus Group, and the Fund for Medical Research and Education (Detroit); has consulted for Map Pharmaceuticals, Gray Consulting, Smith Research, Inc, Quintiles/Innovax, International Meetings and Science, and Sciencomics; and has given talks and consulted for AstraZeneca. S. P. Peters has served on advisory boards and/or given talks for Abbott, AdvancMed, AsthmaX, AstraZeneca, Bristol-Meyers Squibb, Creative Educational Concepts, Med, Dyer, GlaxoSmithKline, and the National Institutes of Health. S. C. Lazarus and R. J. Martin have received research support from the National Institutes of Health, Novartis, and Boehringer-Ingelheim, Centocor, Ception, Genentech, GlaxoSmithKline, and the National Institutes of Health. C. A. Sorkness has served on advisory boards for GlaxoSmithKline, Schering-Plough, AstraZeneca, and Novartis and has received research support from Schering-Plough and Compleware/Sandoz. S. J. Szefler has consulted for GlaxoSmithKline, Genentech, Merck, Boehringer-Ingelheim, Novartis, and Schering-Plough and has received research support from the National Institutes of Health, National Heart, Lung, and Blood Institute, National Institute of Allergy and Infectious Diseases, GlaxoSmithKline, and the National Institute of Environmental Health Sciences/Environmental Protection Agency. I. Wasserman has received research support from Merck, consulted for Schering, and provided legal consultation or expert witness testimony on the subject of mold allergy. The rest of the authors have declared that they have no conflict of interest.

Received for publication April 15, 2010; revised June 23, 2010; accepted for publication July 13, 2010.

Reprint requests: E. Rand Sutherland, MD, MPH, National Jewish Health, 1400 Jackson Street, J-201, Denver, CO 80206. E-mail: sutherland@njheal.org.

© 2010 American Academy of Allergy, Asthma & Immunology
doi:10.1016/j.jaci.2010.07.024
Colonization of the upper and lower airways with typical and atypical bacterial pathogens has been postulated to be an important factor in the development and persistence of asthma. 1,2 Serologic studies have suggested that the atypical bacterium Chlamydomphila pneumoniae (formerly Chlamydia pneumoniae) may be associated with an increased risk of asthma. 3 In addition, studies using PCR to identify atypical bacteria in patients with stable persistent asthma have indicated that approximately 56% manifest evidence of Mycoplasma pneumoniae or Chlamydomphila pneumoniae in the upper or lower airway, a prevalence significantly higher than in the airway of healthy individuals. 4,5 Although PCR evidence of lower airway M pneumoniae or C pneumoniae has been associated with increased airway inflammation, including increased numbers of mast cells in the airway and increased airway epithelial mucin production, 2,6 studies have failed to identify a specific clinical asthma phenotype in those patients with asthma who demonstrate PCR positivity for these organisms.

The suggestion that chronic bacterial colonization or infection with atypical bacteria might play a significant role in asthma has raised the possibility that macrolide antibiotics could be of benefit in patients with persistent asthma and evidence of infection or colonization with these organisms. However, previous studies have not demonstrated uniform benefit to patients with asthma in this regard, with 1 study reporting that small, nonsustained improvements in peak flow and asthma control could be seen with 6 weeks of roxithromycin treatment in individuals with asthma and IgG seropositivity to C pneumoniae. 6 and another suggesting that only those with lower airway PCR evidence of M pneumoniae or C pneumoniae experienced improvements in lung function in response to 6 weeks of treatment with clarithromycin. 7 However, clarithromycin has been shown to modulate sputum IL-8 concentrations and airway neutrophil activation in patients with refractory, noneosinophilic asthma, 8 suggesting that certain phenotypic characteristics may predict clinical response to macrolide antibiotics in asthma. Notwithstanding, a systematic review of the use of macrolides in chronic asthma concluded that there is not currently enough evidence either to support or to reject the use of macrolides in chronic asthma, and that additional studies were needed to address this clinical question in patients with asthma and in subsets thereof, including patients with evidence of atypical bacterial colonization or infection. 9 International asthma care guidelines also highlight this question as an area of ongoing uncertainty. 10,11

To evaluate prospectively the interrelationship between lower airway PCR evidence of M pneumoniae or C pneumoniae, response to treatment with clarithromycin, and asthma phenotype, we conducted a randomized, controlled trial of clarithromycin versus placebo added to inhaled fluticasone propionate in patients with suboptimally controlled asthma. We hypothesized that the addition of a macrolide antibiotic to an inhaled corticosteroid (ICS) would improve asthma control over that achieved with ICS alone, and we used a stratification-by-PCR design to test this hypothesis concurrently and independently in 2 separate groups of patients, those with and those without evidence of M pneumoniae or C pneumoniae in the lower airways.

METHODS

The Macrolides in Asthma study (Clinicaltrials.gov identifier NCT00318708) was conducted by the National Heart, Lung, and Blood Institute (NHLBI)–funded Asthma Clinical Research Network (ACRN) between July 2006 and March 2009 at 10 sites throughout the United States. The study was approved by each site’s institutional review board, and all participants provided written informed consent. The study protocol was developed by the ACRN steering committee, reviewed and approved by an NHLBI-convened protocol review committee, and monitored by an independent data and safety monitoring board.

Participants were eligible to enroll if they had a clinical diagnosis of asthma and either bronchodilator responsiveness, defined as an increase of 12% or greater in the FEV₁ 15 minutes after the administration of 2 puffs of albuterol, or airway hyperresponsiveness, measured by the PC₂₀, FEV₁ to methacholine of ≤16 mg/mL. Participants also were required to demonstrate suboptimally controlled asthma at the time of enrollment, as defined by threshold scores on the Juniper Asthma Control Questionnaire (ACQ) of ≥1.5 in those not receiving ICS-containing treatments. Participants receiving ICS-containing treatments could be enrolled with an ACQ score ≥1.25 at enrollment or if in the opinion of the investigator the ACQ score was likely to be ≥1.25 at the end of the run-in period. 12,13 These values were derived from and validated in data from the Gaining Optimal Asthma Control trial of Bateman et al. 12,14 All data were obtained by using techniques and procedural standards used in previous ACRN studies. 15,16

After qualifying, participants were enrolled in a 4-week run-in period in which they were treated with chlorofluorocarbon-fluticasone propionate metered dose inhaler (GlanxSmithKline, Research Triangle Park, NC), 88 µg inhaled regularly twice daily, and inhaled chlorofluorocarbon-albuterol sulfate, 180 µg as needed every 4 to 6 hours for relief of acute symptoms. If, at the end of the 4-week run-in period, participants demonstrated an ACQ score of ≥1.25, they were eligible to proceed to fiberoptic bronchoscopy for the purposes of endobronchial biopsy for characterization of lower airway PCR status for M pneumoniae or C pneumoniae. Fiberoptic bronchoscopy was performed according to standard investigative procedures, 17,18 and a standardized approach to biopsy was used, with between 4 and 8 biopsies obtained from the lobar, segmental, or subsegmental airways in the right lower and middle lobes. DNA was extracted from these biopsies according to standard methodology, and a nested quantitative PCR protocol was used, with primers and probes specific for genomic DNA of the 16s ribosomal subunits of M pneumoniae and C pneumoniae, the M pneumoniae P1 adhesin and the C pneumoniae RNA polymerase 1.4,19-21 On the basis of the results of PCR testing, participants were stratified into 1 of 2 groups, either PCR-positive (for any of the above genes) or PCR-negative for both M pneumoniae and C pneumoniae. Within these 2 strata, participants were randomly allocated in a 1:1 distribution to the addition of either clarithromycin (DAVA Pharmaceuticals Inc, Fort Lee, NJ), 500 mg capsule by mouth twice daily, or matched placebo (FMC Corp, Philadelphia, Pa) capsule by mouth twice daily, to continued regularly scheduled fluticasone propionate and as-needed albuterol sulfate for 16 weeks (112 days). Both participants and study personnel were blind to treatment allocation.

The primary outcome variable was the change in the 7-item ACQ score between the time of randomization and 16 weeks of study treatment, evaluated independently in each PCR stratum. The previously established minimal clinically important difference of a change in 0.5 units in ACQ score was used to identify treatment response. 12 Secondary outcomes included change in lung function (FEV₁, morning and evening peak flow), change in rescue albuterol use, change in exacerbation number and frequency, change in PC₂₀, and change in exhaled nitric oxide concentration. Main study conclusions were based on the primary outcome variable, and corrections for multiple significance testing with regard to secondary outcomes were not prespecified. 12

It was estimated that 72 participants per PCR stratum would be needed to achieve 90% power to detect a difference of 0.5 in the change in the ACQ score
between clarithromycin and placebo treatment arms in each of the 2 PCR strata, and an approximately equal distribution between PCR-positive and PCR-negative individuals was anticipated.\(^2\) Stratified repeated-measures analysis of covariance was used to analyze change in primary and secondary outcomes within each PCR stratum, with models adjusted for study site, sex, race, age, FEV\(_1\) percent predicted, and asthma duration. As a prespecified secondary analysis, repeated-measures analysis of covariance was also used to analyze the difference between clarithromycin and placebo in the combined study population, irrespective of PCR status. Categorized threshold changes in ACQ were compared between treatment groups by using Mantel-Haenszel \(\chi^2\) tests, with additional analyses using Kaplan-Meier survival estimates to evaluate difference in time to achieving threshold changes in ACQ score. Logistic regression was used to identify predictors of PCR status, and predictors of response to clarithromycin were evaluated by using linear regression. All analyses invoked the intent-to-treat paradigm, with truncation at the time of exacerbation or treatment failure in relevant analyses. SAS version 9.1 (SAS Institute, Cary, NC) was used for all analyses.

**RESULTS**

**Baseline characteristics of participants**

Two hundred fifty-three participants met criteria for enrollment into the study, with 92 participants proceeding to randomization because of continued suboptimal asthma control at the end of the 4-week run-in period (Fig 1). Twelve (13%) of the 92 randomized participants demonstrated PCR evidence of *M pneumoniae* on endobronchial biopsy, with 1 also demonstrating concurrent PCR evidence for *C pneumoniae*. Eighty participants did not demonstrate PCR evidence of *M pneumoniae* or *C pneumoniae*. This proportion of PCR-positive to PCR-negative participants was less than anticipated during trial planning, resulted in the PCR-negative stratum being fully enrolled first, and suggested that 8 bronchoscopies would be required to identify each additional PCR-positive subject. On the basis of this information obtained during trial execution, it was concluded that full enrollment of the PCR-positive arm of the study was not feasible, and further enrollment and bronchoscopic characterization was discontinued. Across the 2 PCR strata, participants were well matched with regard to physiologic and inflammatory biomarkers (Table I).

**Change in asthma control in response to clarithromycin treatment**

In those participants who were PCR-negative for *M pneumoniae* or *C pneumoniae* (n = 80), 16 weeks of clarithromycin added to fluticasone resulted in a 0.4 ± 0.1 unit reduction in the ACQ (Fig 2), compared with a 0.2 ± 0.1 unit reduction in those allocated to placebo plus fluticasone, indicative of a nonsignificant between-group difference of 0.2 ± 0.2 units (P = .3). In those participants who were PCR-positive for *Mycoplasma* or *Chlamydophila* (n = 12), 16 weeks of clarithromycin added to fluticasone resulted in a 0.4 ± 0.4 unit reduction in the ACQ versus a 0.1 ± 0.3 unit reduction in those allocated to placebo plus fluticasone, a between-group difference of 0.3 ± 0.5 units (P = .6) that was also not significant. When response to clarithromycin versus placebo was evaluated in all participants, irrespective of PCR status, 16 weeks of clarithromycin added to fluticasone resulted in a 0.4 ± 0.1 unit reduction in the ACQ, with a 0.2 ± 0.1 unit reduction in those allocated to placebo plus fluticasone, a between-group difference of 0.2 ± 0.2 units (P = .2).

A prespecified secondary time-to-event analysis was conducted evaluating the effect of clarithromycin versus placebo, within PCR strata, evaluating time at which the minimal clinically
important difference of a 0.5-unit reduction in the ACQ score was achieved (Fig 3). In those participants who were PCR negative for \emph{M pneumoniae} or \emph{C pneumoniae}, there was no difference between treatment groups (log-rank $\chi^2 = .79; P = .4$). However, in participants who were PCR positive for \emph{M pneumoniae} or \emph{C pneumoniae}, there was weak evidence of a more rapid achievement of a reduction in ACQ score $\geq 0.5$, with a log-rank $\chi^2 = 3.55$ ($P = .06$). When the analysis was conducted independent of PCR status, there was no evidence of a statistically significant difference between the groups (log-rank $\chi^2 = 2.39; P = .1$).

Additional prespecified secondary analyses were performed to determine the proportion of participants who achieved reductions in the ACQ score of equal to or greater than the predefined minimal clinically important difference of 0.5 units.\textsuperscript{12} When adjusted for PCR status, Mantel-Haenszel $P$ values for the effect of clarithromycin versus placebo were $P = .1$ for a change in ACQ of $\geq 0.5$ (which occurred in 12 subjects treated with clarithromycin and 6 with placebo), $P = .06$ for a change in ACQ of $\geq 0.75$ (which occurred in 9 subjects treated with clarithromycin and 3 with placebo), and $P = .08$ change in ACQ of $\geq 1.0$ (which occurred in 7 subjects treated with clarithromycin and 2 with placebo), respectively.

**Physiologic, inflammatory, and clinical parameters and response to clarithromycin treatment**

There was no significant effect of clarithromycin on markers of lung function including morning and evening peak flow, pre-albuterol FEV$_1$ (L or percent predicted), and maximum bronchodilator response (Table II), all secondary outcomes. However, in those participants who were PCR-negative for \emph{M pneumoniae} or \emph{C pneumoniae}, 16 weeks of clarithromycin added to fluticasone resulted in a 1.6 ± 0.3 doubling dose increase in the PC$_{20}$, with a 0.4 ± 0.3 doubling dose increase in those allocated to placebo plus fluticasone, a between-group difference of 1.2 ± 0.5 doubling doses ($P = .02$) favoring clarithromycin. A differential effect of clarithromycin versus placebo on PC$_{20}$ methacholine was not observed in those participants who were PCR-positive for \emph{M pneumoniae} or \emph{C pneumoniae}, although a significant effect of clarithromycin was observed when data were analyzed independent of PCR status, with a between-group difference of 1.2 ± 0.5 doubling doses ($P = .02$).

Treatment with clarithromycin did not alter bronchodilator responsiveness or improve the concentration of exhaled nitric oxide, nor did it improve quality of life as measured by the Asthma Quality of Life Questionnaire. However, a weak association between a reduction in the need for rescue bronchodilator and clarithromycin treatment was seen in the study population as a whole, with an overall reduction in need for rescue albuterol of 0.6 ± 0.3 puffs per day (–0.7 puffs/d in clarithromycin-treated participants vs –0.1 puffs/d with placebo), with a $P = .06$. With regard to upper airway disease, there was no significant effect of clarithromycin on the development of self-reported sinusitis or rhinitis during the study ($P = .1$).

Finally, to determine whether prerandomization sputum eosinophils or neutrophils were predictive of response to clarithromycin, we modeled the effect of clarithromycin on our primary outcome (ACQ) independent of PCR status with regard to (1) sputum eosinophils stratified as $\leq$3% or $>$3%, (2) percent sputum eosinophils treated as a continuous variable, and (3) percent sputum neutrophils treated as a continuous variable. There were no statistically significant differences in the effect of clarithromycin on asthma control with regard to the percent of either of these cell types in induced sputum, with $P = .8$ for eosinophils dichotomized at 3%, $P = 1.0$ for eosinophils (continuous), and $P = .5$ for neutrophils (continuous).

**Serology, PCR status, and response to clarithromycin**

Of those randomized subjects with available serologic data ($n = 81$), 36 (44%) were seropositive for \emph{C pneumoniae} IgA, 54
(67%) for *C pneumoniae* IgG, and 3 (4%) for *C pneumoniae* IgM. Serology for *M pneumoniae* demonstrated that 55 (68%) were seropositive for *M pneumoniae* IgG and 1 for *M pneumoniae* IgM. Serologic status (dichotomized) was not found to be predictive of endobronchial biopsy PCR positivity; a positive *C pneumoniae* IgA status was only 62.5% sensitive and 57.5% specific for positive endobronchial biopsy PCR for *C pneumoniae*, and a positive *M pneumoniae* IgG status was 88% sensitive and 34% specific for endobronchial biopsy *M pneumoniae* PCR positivity. Serologic status (positive or negative) was not predictive of improvement in ACQ score with clarithromycin treatment, with the *C pneumoniae* IgA F = 2.22 (*P* = .2) and the *M pneumoniae* IgG F = 0.80 (*P* = .4). In analyses in which serologic results were treated as continuous variables, no significant association was observed between increasing concentrations of either *C pneumoniae* IgA or *M pneumoniae* IgG and the effect of clarithromycin on ACQ (data not shown).

### Adverse events

Participants allocated to clarithromycin were not more likely than those allocated to placebo to experience drug-related adverse events, including increased likelihood of gastrointestinal symptoms or respiratory tract infections.

### DISCUSSION

This PCR-stratified, double-blind, randomized controlled trial of clarithromycin or placebo added to fluticasone in patients with suboptimally controlled persistent asthma demonstrated that there is not a beneficial effect on asthma control of adding clarithromycin to inhaled fluticasone in patients similar to those entered into this trial. The PCR-negative approach allowed us to test the effect of clarithromycin on asthma control independently in patients who did and did not have molecular evidence of atypical bacteria in the lower airways. Given full enrollment of the PCR-negative stratum, we have robustly demonstrated a lack of effect in those who do not demonstrate PCR evidence of *M pneumoniae* or *C pneumoniae* on endobronchial biopsy, as well as in the study population as a whole when analyzed independent of PCR status. However, the underenrollment of the PCR-positive stratum resulted in inadequate power to test robustly the effect of clarithromycin in the PCR-positive subpopulation, leaving the question of efficacy in this group of patients with asthma as yet unanswered. Our findings address an area of uncertainty in asthma pharmacotherapy7,9-11 and provide evidence that clarithromycin should not be considered as an addition to ICSs to improve disease control in patients with suboptimally controlled mild-to-moderate persistent asthma who are PCR-negative for *C pneumoniae* and *M pneumoniae*, a group that constituted 87% of the participants enrolled in this study and therefore possibly the majority of the adult asthma population as well. In addition, our results suggest that *C pneumoniae* and *M pneumoniae* serologic evaluation is of minimal clinical utility in this setting, because serology predicted neither PCR status nor response to clarithromycin.

Although there was no effect of adding clarithromycin to fluticasone on physiologic measures of airflow or bronchodilator response, there was a clinically and statistically significant effect of clarithromycin on airway hyperresponsiveness in PCR-negative participants, as indicated by a doubling of the concentration of methacholine required to produce a 20% decline in FEV1 in those allocated to clarithromycin. This occurred despite the fact that all participants were being treated concurrently with fluticasone and suggests that nonantibiotic effects of clarithromycin on airway smooth muscle functional or inflammatory phenotype can be seen even in patients treated with ICSs. The improvement in airway hyperresponsiveness with clarithromycin in patients with asthma already receiving ICSs is of interest, augments previous reports from small uncontrolled clinical studies,23-27 and supports previous observations that macrolides might modulate this effect through nonantimicrobial pathways including alteration of cholinergic signaling pathways or attenuation of endothelin-1 expression by airway epithelial cells.25-27

In addition, although clarithromycin did not have a beneficial effect on exhaled nitric oxide or asthma-specific quality of life, it was weakly associated with a reduction in the need for rescue albuterol use, both in PCR-negative subjects and in the population as a whole. Of additional interest (although not definitive) were our findings with regard to the time to achievement of a clinically significant improvement in asthma control, where those participants who were PCR-positive achieved a 0.5-unit improvement in the ACQ more rapidly than did those who were PCR-negative. Similarly, clarithromycin treatment was associated with a greater likelihood of achieving improvements in the ACQ that exceeded the minimal clinically important difference. Although these results are subject to the limitation of the small sample size in the PCR-positive stratum and are secondary outcomes, they raise...
the possibility that there may be a relevant interaction between PCR status and response to clarithromycin.

The results of this study are likely generalizable to most adults with mild-to-moderate persistent asthma, although extrapolation to severe disease may not be appropriate given the lack of enrollment of participants with severe asthma into this trial. The PCR-negative stratum of the study (which accounted for 87% of study participants) was adequately powered to detect an effect of clarithromycin on asthma control and did not. A similar lack of effect was observed in analyses in which all participants (independent of PCR status) were included, indicating a lack of benefit of clarithromycin overall. In addition, we enrolled adults with asthma that remained suboptimally controlled despite low-dose ICS monotherapy. This subset of individuals likely accounts for a substantial proportion of the population with asthma,\(^{14}\) and for them, guidelines recommend either increasing the dose of ICSs or adding a second asthma controller medication such as a long-acting \(\beta_2\) agonist.\(^{10,11}\) In this context, our findings indicate that clarithromycin should not be considered as the next therapeutic step in patients with mild and moderate persistent asthma. Although weak trends were observed toward a favorable effect of clarithromycin on asthma control in PCR-positive patients, these findings were not statistically significant and cannot be considered conclusive. Thus, while there may be a beneficial effect of clarithromycin in those with evidence of \(M\ pneumoniae\) or \(C\ pneumoniae\) or in other patient populations not included in our study (eg, those with more severe or neutrophil-predominant asthma\(^{8}\)), further research will be required to assess definitively the role of macrolide antibiotics in these subpopulations.

Certain features of the study design should be considered when interpreting these results. Clarithromycin was chosen because, when compared with other macrolides, it is preferentially concentrated in the lung epithelial lining fluid.\(^{28,29}\) it may be less likely to contribute to antimicrobial resistance than other members of the macrolide family,\(^{30,31}\) its side effect profile with extended treatment period has been described,\(^{32,33}\) it is unlikely to alter fluticasone pharmacokinetics significantly,\(^{34}\) and it has been previously used in asthma.\(^{7}\) However, it is possible that the antimicrobial or anti-inflammatory effects might have been greater had another member of the macrolide class been chosen. Of note, the absence of a significant improvement in asthma control in both the entire study population and the PCR-negative subset suggests that an effect of clarithromycin on glucocorticoid metabolism, similar to that previously described with the macrolide antibiotic troleandomycin,\(^{35,36}\) was not present.

Another novel feature of this study is the choice of asthma control, a composite variable that differs from quantitative physiologic or inflammatory parameters, as the primary outcome variable. This outcome measure was chosen for several reasons: it is patient-centered, taking clinical variables such as symptoms and \(\beta\)-agonist use into account, it is a reliable technique for assessing asthma disease activity and control, and it incorporates a quantitative measure of airflow in the FEV\(_1\). It is possible that the use of a composite variable could have obscured the effect of clarithromycin in 1 or more clinical or physiologic domains, but we did not show a clear benefit of clarithromycin on lung function, and only a weak trend toward a reduction in rescue bronchodilator use was observed.

Complete enrollment of the PCR-positive arm of this trial was hampered by a lower than anticipated prevalence of PCR positivity for \(M\ pneumoniae\) and \(C\ pneumoniae\). A previous study indicated that PCR evidence of these organisms could be found in 56% of adults with asthma, with 30% demonstrating these organisms in the lower airway,\(^{2}\) whereas in this trial, overall lower airway positivity was 13%. Although the reason for this reduced prevalence in our study is not clear, the previous report of Martin et al\(^{2}\) suggested the possibility of a reduction in the likelihood of PCR positivity in those participants who were using ICS. Because the run-in and treatment periods of this study exposed all participants to a fixed continuous dose of fluticasone, it is possible that this treatment reduced the prevalence of PCR positivity for \(M\ pneumoniae\) and \(C\ pneumoniae\) in our study population. Given that the technical approaches to obtaining and processing endobronchial biopsies used in this study were similar to those previously used by investigators in this area,\(^{7,27}\) we believe it is unlikely that technical factors alone explain the difference. Whatever the cause, given the fact that the PCR-positive group did not have adequate enrollment to test robustly the effect of supplemental clarithromycin in this group, it remains unknown whether clarithromycin is of clinical benefit in patients who are PCR-positive for either \(M\ pneumoniae\) and \(C\ pneumoniae\).

### TABLE II. Effect of clarithromycin on outcomes in PCR-stratified and aggregate analyses

<table>
<thead>
<tr>
<th>Variable</th>
<th>Clarithromycin effect</th>
<th>Clarithromycin effect</th>
<th>Clarithromycin effect</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PCR- participants</td>
<td>PCR+ participants</td>
<td>independent of PCR</td>
</tr>
<tr>
<td>Physiologic</td>
<td>Mean ± SE</td>
<td>P value</td>
<td>Mean ± SE</td>
</tr>
<tr>
<td>Pre-albuterol FEV(_1) (L)</td>
<td>−0.02 ± 0.1</td>
<td>.8</td>
<td>+0.04 ± 0.2</td>
</tr>
<tr>
<td>Pre-albuterol FEV(_1) (% predicted)</td>
<td>+0.2 ± 1.8</td>
<td>.9</td>
<td>+1.0 ± 3.9</td>
</tr>
<tr>
<td>Morning peak flow (L/min)</td>
<td>+3.4 ± 6.4</td>
<td>.6</td>
<td>−9.3 ± 10.8</td>
</tr>
<tr>
<td>Evening peak flow (L/min)</td>
<td>−0.3 ± 6.6</td>
<td>.9</td>
<td>−18.8 ± 13.0</td>
</tr>
<tr>
<td>Methacholine PC(_{20}) doubling dose</td>
<td>+1.2 ± 0.5</td>
<td>.02</td>
<td>+0.9 ± 1.8</td>
</tr>
<tr>
<td>Inflammatory</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FeNO (ppb)</td>
<td>−3.4 ± 4.5</td>
<td>.5</td>
<td>−11.4 ± 11.9</td>
</tr>
<tr>
<td>Clinical</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asthma Quality of Life</td>
<td>+0.2 ± 0.2</td>
<td>.4</td>
<td>−0.1 ± 0.6</td>
</tr>
<tr>
<td>Questionnaire Score</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rescue albuterol use (puffs/d)</td>
<td>−0.6 ± 0.3</td>
<td>.09</td>
<td>−0.4 ± 0.5</td>
</tr>
</tbody>
</table>

FeNO. Exhaled nitric oxide.
In conclusion, this study demonstrated that there is not a beneficial effect on asthma control or lung function of adding clarithromycin to fluticasone in adults with persistent, suboptimal asthma. There was a significant reduction in airway hyperresponsiveness seen with clarithromycin treatment in this study, occurring in the absence of concordant improvements in multiple other clinical and physiologic parameters. Although our findings do not support a role for clarithromycin in the treatment of suboptimally controlled asthma, particularly in those without evidence of *Mycoplasma* or *Chlamydia* in the lower airway, further studies are warranted to characterize the role of microbial communities in the asthmatic airway and to determine whether evidence of bacterial colonization or infection in the lower airway is predictive of asthma phenotype or clinical improvement with antibiotic treatment.

We acknowledge the study participants for their contributions, the ACRN coordinator staff for execution of the protocol, and Robert A. Smith, PhD, of the NHLBI for his support of this trial.

**Clinical implications:** The Macrolides in Asthma trial evaluated whether clarithromycin improved control of mild-to-moderate persistent asthma above that achieved with low-dose fluticasone alone. Clarithromycin did not improve asthma control, lung function, or quality of life but did improve airway hyperresponsiveness.

**REFERENCES**